Vestibular Schwannoma Koos Grade II International Study of Active Surveillance Versus Stereotactic Radiosurgery: The VISAS-K2 Study
- PMID: 39503444
- DOI: 10.1227/neu.0000000000003216
Vestibular Schwannoma Koos Grade II International Study of Active Surveillance Versus Stereotactic Radiosurgery: The VISAS-K2 Study
Abstract
Background and objectives: This study assessed the efficacy and safety of stereotactic radiosurgery (SRS) in comparison with watchful waiting for managing Koos grade II vestibular schwannomas (VS).
Methods: A retrospective, multicentric analysis was conducted, focusing on patients with Koos grade II VS who either received SRS (SRS group) or were observed (observation group). To ensure comparability between groups, propensity score matching was used, including factors such as demographic characteristics, tumor dimensions, and hearing assessments. The primary end points examined were tumor control, maintenance of serviceable hearing, and neurological outcomes.
Results: A total of 92 patients were equally matched across both cohorts, with a median follow-up of 37 months for the SRS group and 27.5 months for those observed. The SRS cohort exhibited superior tumor control over observation across 3, 5, and 8 years, achieving a 100% control rate vs 47.9%, 40.1%, and 34.3% for the observation group at these time intervals, respectively ( P < .001). Serviceable hearing preservation rates were comparable between the 2 groups throughout 3, 5, and 7 years (72.9% for SRS vs 65.4% for observation at 3 years; P = .86). Moreover, SRS management correlated with a lower incidence of vestibular symptoms (odds ratio = 0.11, P = .002), with no significant disparity in the deterioration of cranial nerve (CN) V or CN VII functions. Notably, the likelihood of experiencing any CN impairment was significantly diminished in the SRS cohort (odds ratio = 0.47, P = .04).
Conclusion: For patients with Koos grade II VS, SRS offers superior tumor control rate and a lower risk of CN dysfunction without sacrificing hearing preservation.
Copyright © Congress of Neurological Surgeons 2024. All rights reserved.
References
-
- Thomsen J, Charabi S, Tos M, Mantoni M, Charabi B. Intracanalicular vestibular schwannoma--therapeutic options. Acta Otolaryngol Suppl. 2000;543:38-40.
-
- Barnes JH, Patel NS, Lohse CM, Tombers NM, Link MJ, Carlson ML. Impact of treatment on vestibular schwannoma-associated symptoms: a prospective study comparing treatment modalities. Otolaryngol Head Neck Surg. 2021;165(3):458-464.
-
- Bird PA, MacFarlane MR. Management of unilateral vestibular schwannoma/acoustic neuroma. N Z Med J. 2007;120(1265):U2805.
-
- Lund-Johansen M. Treatment of small and medium-sized vestibular schwannoma-a need for better evidence. Acta Neurochir (Wien). 2019;161(1):87-89.
-
- Quesnel AM, McKenna MJ. Current strategies in management of intracanalicular vestibular schwannoma. Curr Opin Otolaryngol Head Neck Surg. 2011;19(5):335-340.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
